Clinical Neuromuscular Pathology C-Cert Learning Objectives and CME

C-cert Activity Description

The Continuous Certification (C-cert) activities provide subspecialty learning and knowledge assessment to ensure that diplomates are staying up to date on the latest science, treatments, and therapeutics relating to their subspecialty. The annual activities include: 1) reading the subspecialty Reading List of journal articles, and 2) taking and passing the 25-question online post-reading quiz to assess knowledge gained from the journal article content. 

Learning Objectives

Upon completion of this UCNS C-cert activity, participants will be able to:
  • Recognize common congenital myopathies in adulthood and distal myopathies in relation to clinical-pathological phenotype
  • Understand role and limitation of muscle, nerve and skin biopsies in light of novel knowledge on specific neuromuscular disorders and outcomes
  • Correlate clinical and pathological features of immune-mediated myopathies with serological findings

Core Competencies

This UCNS C-cert activity covers the following core competency:
  • Medical Knowledge

AMA Credit Designation Statement

The American Academy of Neurology Institute designates this enduring material for a maximum of 11 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Medical Education (CME) Instructions

To claim CME credits, answer question 26 on the quiz to reflect the total time spent completing the required reading and online quiz. This question is not included in the scoring of the quiz. A passing score of 80% of higher is needed to meet C-cert requirements and receive CME credit. CME credit confirmation will be emailed within ten business days of passing the quiz.

ACCME Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the American Academy of Neurology Institute (AANI) and United Council for Neurologic Subspecialties. The AANI is accredited by the ACCME to provide continuing medical education for physicians.

Disclosures

The UCNS complies with all standards and policies of the ACCME, including identification and resolution of all conflicts of interest prior to the educational activity being delivered to learners. Accordingly, UCNS  planners, authors, and staff comply with the UCNS’s Conflicts of Interest Policy

Clinical Neuromuscular Pathology Certification Examination Committee Contributors


P. James B. Dyck, MD, FAAN, Chair, Mayo Clinic

Disclosures: Receives fees from Akcea  pharmaceutical for speaking about TTR amyloid neuropathy.

Robert C. Bucelli, MD, PhD, Washington University School of Medicine
Disclosures: Receives research support from Biogen for multiple ALS ASO trials at Washington University. Role: Principal investigator.

Andrea M. Corse, MD, Johns Hopkins University School of Medicine
Disclosures: Received research funding from Biogen to present A Phase I, Multiple-Ascending-Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of BIIB078 Administered Intrathecally to Adults with C9ORF72-Associated Amyotrophic Lateral Sclerosis.

Praful Kelkar, MD, FAANEM, Minneapolis Clinic of Neurology
Disclosures: Receives speaker honoraria from Teva and  Sanofi Genzyme.

Justin Yuan-Ping Kwan, MD, Temple University
Disclosures: Nothing to disclose.

Steven Lovitt, MD, The Neurology Center
Disclosures: Receives speaker fees from Alexion Pharmaceuticals.

Michelle L. Mauermann, MD, Mayo Clinic
Disclosures: Receives research support from Alnylam for TTR amyloid clinical trial and from IONIS for TTR amyloid clinical trial.

Margherita Milone, MD, PhD, Mayo Clinic
Disclosures: Receives compensation for serving as associate editor of Neurology Genetics; Receives research funding by Mayo Clinic benefactor.

Aziz Shaibani, MD, FACP, FAAN, Baylor College of Medicine
Disclosures: Received compensation to serve on Stealth BioTherapeutics advisory board regarding primary mitochondrial myopathy (PMM) and elamipretide.

Staff Contact

Todd Bulson, Senior Manager Certification
tbulson@ucns.org
(612) 928-6067

Becky Swanson, Executive Assistant
bswanson@ucns.org
(612) 928-6050